Figure S1 from Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid TumorsAmita Patnaik, Anthony W. Tolcher, S. Peter Kang et al.|Unknown|2023Cited by 0
Supplementary Tables S1-2, Figure 1 from Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid TumorsAmita Patnaik, Anthony W. Tolcher, S. Peter Kang et al.|Unknown|2023Cited by 0
Data from Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid TumorsAmita Patnaik, Anthony W. Tolcher, Adil Daud et al.|Unknown|2023Cited by 0
Data from Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid TumorsAmita Patnaik, Anthony W. Tolcher, S. Peter Kang et al.|Unknown|2023Cited by 0
Figure S1 from Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid TumorsAmita Patnaik, Anthony W. Tolcher, S. Peter Kang et al.|Unknown|2023Cited by 0